B. Riley Initiates Coverage on Insulet Corporation to Neutral

B. Riley Initiates Coverage on Insulet Corporation(NASDAQ:PODD). The shares have been rated Neutral. The rating by B. Riley was issued on Sep 27, 2016.

In a different note, On Aug 4, 2016, Jefferies said it Maintains its rating on Insulet Corporation. In the research note, the firm Raises the price-target to $41.00 per share. The shares have been rated ‘Buy’ by the firm.

Insulet Corporation (PODD) made into the market gainers list on Fridays trading session with the shares advancing 3.57% or 1.41 points. Due to strong positive momentum, the stock ended at $40.94, which is also near the day’s high of $41.07. The stock began the session at $40.42 and the volume stood at 7,97,877 shares. The 52-week high of the shares is $45.595 and the 52 week low is $23.94. The company has a current market capitalization of $2,345 M and it has 5,72,67,862 shares in outstanding.

Insulet Corporation(PODD) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $87.33M. Analysts had an estimated revenue of $81.19M. Earnings per share were $-0.08. Analysts had estimated an EPS of $-0.17.

Several Insider Transactions has been reported to the SEC. On May 27, 2016, Regina O Sommer (director) sold 8,019 shares at $30.42 per share price.Also, On May 19, 2016, Patrick J Sullivan (CEO) purchased 45,000 shares at $26.98 per share price.On May 16, 2016, Bradley A Thomas (EVP Human Resources) purchased 2,975 shares at $26.63 per share price, according to the Form-4 filing with the securities and exchange commission.

Insulet Corporation is a medical device company engaged in the development manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System) an insulin infusion system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica Massachusetts. Features of the OmniPod System include two-part design no tubing and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod a small lightweight disposable insulin infusion device worn beneath clothing; and the PDM a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Insulet Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Insulet Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.